Abiraterone acetate preferentially enriches for the gut commensal *Akkermansia muciniphila* in castrate-resistant prostate cancer patients
B. A. Daisley, R. M. Chanyi, et al.
Explore these studies to deepen your understanding
Adjacent work that informs or extends this paper's methodology and findings.
The efficacy and adverse events of conventional and second-generation androgen receptor inhibitors for castration-resistant prostate cancer: A network meta-analysis
X. Zhang, G. Zhang, et al.
Health-related quality of life, psychological distress, and fatigue in metastatic castration-resistant prostate cancer patients treated with radium-223 therapy
M. J. V. D. Doelen, I. M. Oving, et al.
Impact of enzalutamide on patient-reported fatigue in patients with prostate cancer: data from the pivotal clinical trials
B. F. Tombal, S. J. Freedland, et al.
Efficacy of early PET-CT directed switch to carboplatin and paclitaxel based definitive chemoradiotherapy in patients with oesophageal cancer who have a poor early response to induction cisplatin and capecitabine in the UK: a multi-centre randomised controlled phase II trial
S. Mukherjee, C. N. Hurt, et al.
